Effects of paliperidone extended release on the symptoms and functioning of schizophrenia

BMC Clinical Pharmacology

Volumn 12, Issue , 2012, Pages

  Huang, Min Wei ^a,b   Yang, Tsung Tsair ^c   Ten, Po Ren ^d   Su, Po Wen ^e   Wu, Bo Jian ^f   Chan, Chin Hong ^b   Lan, Tsuo Hung ^b   Liu, I Chao ^c   Chiu, Wei Cheh ^g   Li, Chun Ying ^a   Cheng, Kuo Sheng ^a   Yeh, Yu Chi ^g  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c Department of Psychiatry   (Taiwan)

^d SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f Yuli Hospital   (Taiwan)

^g CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTPATIENT; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; REMISSION; RHINOPHARYNGITIS; SCHIZOPHRENIA; SOCIAL INTERACTION; SOMNOLENCE; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; DELAYED RELEASE FORMULATION; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; REMISSION INDUCTION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84855431406     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-12-1     Document Type: Article

References (30)

1. World Health Organization Mental health, Disorder management. 2006, World Health Organization., http://www.who.int/mental_health/management/schizophrenia/en/
2. Keshavan MS, Schooler NR. First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992, 18:491-513.
3. Jeffrey LA, Diana P, Aysenil B, Miranda C, Fred J, Kalina B, John G. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001, 50:884-97. 10.1016/S0006-3223(01)01303-8, 11743943.
4. Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early intervention in psychiatry 2010, 4(1):64-78. 10.1111/j.1751-7893.2010.00165.x, 20199482.
5. Rosen K, Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull 2005, 31:735-50. 10.1093/schbul/sbi017, 16123527.
6. Nancy AC, William CT, John KM, Robert LA, Stephen MR, Daniel WR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005, 162:441-449. 10.1176/appi.ajp.162.3.441, 15741458.
7. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008, 23(6):325-31. 10.1097/YIC.0b013e32830c2042, 18854720.
8. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Current Opinion in Psychiatry 2008, 21(2):173-177. 10.1097/YCO.0b013e3282f33f76, 18332666.
9. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007, 95(1-3):143-50. 10.1016/j.schres.2007.05.009, 17644313.
10. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101(4):323-9.
11. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006, 22:1879-92. 10.1185/030079906X132613, 17022845.
12. Herbert MY, William BV, Isaac NF, Rosanne L, David H, Michelle K, Marielle E. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008, 69:817-29. 10.4088/JCP.v69n0515, 18466043.
13. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90(1-3):147-61. 10.1016/j.schres.2006.09.012, 17092691.
14. Marder SR, Kramer M, Ford L, Eerdekens E, Eerdekens M, Lim P. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-70. 10.1016/j.biopsych.2007.01.017, 17601495.
15. Michelle K, George S, Valentinas M, Stuart K, Ujjwala V, Pilar L, Mariëlle E. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, doubleblind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:6-14. 10.1097/JCP.0b013e31802dda4a, 17224706.
16. Priebe S, Watzke S, Hansson L, Burns T. Objective social outcomes index (SIX): A method to summarise objective indicators of social outcomes in mental health care. Acta Psychiatr Scand 2008, 118:57-63. 10.1111/j.1600-0447.2008.01217.x, 18582348.
17. Nicholl D, Nasrallah H, Nuamah I, Akhras K, Gagnon DD, Gopal S. Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Current Medical Research & Opinion 2010, 26(6):1471-84. 10.1185/03007991003798927, 22232312.
18. Michael D, Robin E, Michelle K, Lisa F, Guohua P, Pilar L, Mariëlle E. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebocontrolled study. Schizophr Res 2007, 93:117-30. 10.1016/j.schres.2007.03.003, 17466492.
19. Kawata AK, Revicki DA. Psychometric properties of the personal and social performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res 2008, 17:1247-1256. 10.1007/s11136-008-9400-z, 18855124.
20. Georg J, Daniela S, Nina F, Ute N, Idun U, Henning W, Ludger H, Hans-Werner B, Martin B. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res 2008, 104:287-293. 10.1016/j.schres.2008.04.037, 18595665.
21. Kozma CM, Dirani RG, Canuso CM, Mao L. Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Ann Gen Psychiatry 2010, 9:24. 10.1186/1744-859X-9-24, 2892494, 20525183.
22. Nasrallah H, Morosini PL, Gagnon D. Reliability validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Research 2008, 161:213-224. 10.1016/j.psychres.2007.11.012, 18848731.
23. Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Clinical therapeutics 2010, 32(2):275-92. 10.1016/j.clinthera.2010.02.003, 20206786.
24. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow F. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006, 67:1542-50. 10.4088/JCP.v67n1008, 17107245.
25. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909. 10.4088/JCP.v63n1007, 12416599.
26. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophrenia Research 2009, 13(1):56-64.
27. Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatric disease and treatment 2008, 4(5):949-58. 2626923, 19183785.
28. Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008, 16(1):31-43. 10.1097/JGP.0b013e31815a3e7a, 18165460.
29. Kim CY, Chung S, Lee JN, Kwon JS, Kim do H, Kim CE, Jeong B, Jeon YW, Lee MS, Jun TY, Jung HY. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2009, 24(4):181-8. 10.1097/YIC.0b013e32832c25d7, 19451828.
30. David H, Isaac NF, Pilar L, Allan S, Dennis GD, Margaret R. Independent Effect of Paliperidone Extended Release on Social Functioning Beyond Its Effect on Positive and Negative Symptoms of Schizophrenia A Mediation Analysis. Journal of Clinical Psychopharmacology 2009, 29(5):496-497. 10.1097/JCP.0b013e3181b5f40b, 19745652.